SecurityN / NetSuite, Inc. (64118Q107)
Institutional Owners0
Common Shares Outstanding81,474,696 shares (as of 2016-09-30)

Institutional Stock Ownership and Shareholders

NetSuite, Inc. (NYSE:N) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
NetSuite, Inc. (NYSE:N) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR/A KEYBANK NATIONAL ASSOCIATION/OH 3,535 0 -100.00 391 0 -100.00

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Oracle's New Sales Tool To Grow Cloud Business

2018-05-17 seekingalpha
Oracle (NYSE:ORCL) NetSuite has a new sales tool that could make a real dent into cloud sales specifically focused in the CRM space. Cloud sales are the only segments at ORCL experiencing double-digit sales growth and represent the smallest contribution to revenues. ORCL and nFusz Inc. (OTCQB:FUSZ) have finally announced a formal partnership for the widely anticipated rollout of the integration of nFusz’s notifiCRM, the first interactive video-based CRM, into the NetSuite platform. (120-0)

Why Investment Wealth-Builders Seek Leveraged ETFs

2018-04-29 seekingalpha
This article is a deep-dive learning lesson for those new to or confused by our behavioral analysis of Market-Maker price-range forecasts. (80-0)

Exxon, Caterpillar Weigh on the Dow Friday

2018-04-27 247wallst
April 27, 2018: Markets opened higher again Friday but spent much of the day searching for direction. None of the three major indexes has strayed far from the break-even line. Big tech earnings posted last night couldn’t overcome investor wariness over a lower first reading of Q1 GDP and decided to play defense today. (71-0)

SAP: Port In The Storm

2018-04-25 seekingalpha
SAP reported a surprise beat to Q1 earnings, and shares popped 2.5% amid a market that has struggled with correction territory. (3-0)

Oracle Earnings Preview: The Breakout Holds, But Can They Fix The Cloud Issues?

2018-03-10 seekingalpha
Oracle - one of the 1990s "Original Gangsters" - broke out above its previous $45, April 2000 all-time-high in June '17, but has struggled since that time. (106-2)

CUSIP: 64118Q107